20th September 2026, A/Prof Chee L Khoo (in collaboration with A/Prof Masis Perk)
It has been12 months now since we highlighted on GPVoice that digitalis is making a comeback in the management of heart failure. We pointed out the important role it has in heart failure (HF) but its use was downplayed in most of the major guidelines. This is despite increasing clinical trial data supporting this old, but well tested drug.…
19th September 2026, A/Prof Chee L Khoo
We know that atherosclerosis is likely to be present for years or decades before clinical disease becomes manifest. Current primary prevention of cardiovascular events is guided largely by calculated risk-factor scores or symptoms of ischaemia. However, these scores are strongly influenced by age and tend to assign low risk to young adults, even in the presence of relevant risk-factor exposure.…
5th September, A/Prof Chee L Khoo and A/Prof Shannon Lin
Diabetes-related sarcopenia, characterised by the loss of muscle mass, strength, and function in people with diabetes, is an emerging but under-recognised complication associated with falls, frailty, hospitalisations, and reduced quality of life. I am working closely with researchers at the University of Technology Sydney (UTS) and we are conducting a short survey to understand health professionals’ awareness, knowledge, and current practices relating to diabetes-related sarcopenia.…
29th August 2026, A/Prof Chee L Khoo
The European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause recommend that a holistic approach is taken for women during perimenopause and menopause, not having a sole focus on hormone replacement therapy (HRT)/ menopausal hormone therapy (MHT) (1). It recognised that these women can be appropriately managed in primary care according to recognised guidelines.…
28th August 2026, A/Prof Chee L Khoo
Atherosclerotic cardiovascular disease (ASCVD) is considered an inflammatory condition. Not only is inflammation central to the initiation of ASCVD, it is also responsible for the progression as well as the destabilisation of atherosclerotic plaque leading to ischaemia. This is in addition to the other well known risk factors (e.g. dyslipidaemia, smoking, hypertension etc) for ASCVD.…
13th August 2026, A/Prof Chee L Khoo
We know (maybe better phrased – we think we know) that it is the amyloid-β (Aβ) plaques that are a key driver of pathological processes in Alzheimer’s disease (AD) (1,2). Targeting the Aβ should then prevent or at the very least delay the progression of the dementia. The problem with prevention is that we don’t know who are going to get dementia till there is some cognitive impairment.…
25th July 2026, A/Prof Chee L Khoo
We know that 55-65% patients with type 2 diabetes (T2D) have metabolic dysfunction associated fatty liver disease (MAFLD) (1). We also know that 28% of patients with MAFLD will develop T2D if not already present by the time MAFLD is detected (2). There is emerging evidence that there are profound alterations in oral glucose handling in individuals with MAFLD even before T2D is diagnosed.…
12th July 2026, A/Prof Chee L Khoo
We don’t see many acute pancreatitis in our rooms but the incidence of acute pancreatitis is gradually increasing (1). Many will develop further episodes and some will develop chronic pancreatitis. Although most patients with acute pancreatitis have its mild form, some develop moderate or severe acute pancreatitis, both of which include serious complications and an increased risk for death.…
30th June 2026, A/Prof Chee L Khoo
We have waited for a very long time. We only have one second generation long-acting basal insulin even though degludec have been available overseas for ≥ 10 years now. Insulin degludec (iDeg), in combination with a prandial insulin (insulin aspart) has been available in Australia as Ryzodeg® since 2018. But iDeg on its own?…
28th June 2026, A/Prof Chee L Khoo
It’s all over the news. Teplizumab (Tzield) has just been approved by the Australian Therapeutic Goods Administration (TGA) delay the onset of Stage 3 type 1 diabetes mellitus (T1D) in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes mellitus (1). Wow. But what does that mean for our patients already with T1D or those who are at very high risk of developing T1D?…
10th June 2026, A/Prof Chee L Khoo
We know that if a woman developed gestational diabetes mellitus (GDM), the risk of development of type 2 diabetes (T2D) later in life increases by 4-10 times. We also know that the same woman also have higher risk of developing elements of cardiovascular disease (CVD) including hypertension, atherosclerotic CVD ASCVD and heart failure (HF).…
25th May 2026, A/Prof Chee L Khoo
All of us have more than a few patients with essential hypertension (i.e. hypertension with no secondary causes) who remain hypertensive despite two or three anti-hypertensives. These are patients who are already on an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) plus a calcium channel blocker (CCB) or a diuretic or both.…